Amicus Therapeutics (FOLD) Financials

$14.49 0.00 (0.00%)

As of 04/27/2026

Annual Income Statements for Amicus Therapeutics

This table shows Amicus Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-69	-132	-200	-284	-356	-277	-250	-237	-152	-56	-27
Consolidated Net Income / (Loss)	-69	-132	-200	-284	-356	-277	-250	-237	-152	-56	-27
Net Income / (Loss) Continuing Operations	-69	-132	-200	-284	-356	-277	-250	-237	-152	-56	-27
Total Pre-Tax Income	-70	-132	-204	-449	-356	-274	-242	-242	-150	-29	0.19
Total Operating Income	-69	-130	-182	-442	-304	-247	-206	-212	-77	25	33
Total Gross Profit	1.22	0.00	4.13	31	160	230	271	291	362	475	561
Total Revenue	1.22	0.00	4.96	37	182	261	306	329	399	528	634
Operating Revenue	1.22	-	4.96	37	182	261	306	329	399	528	634
Total Cost of Revenue	0.00	0.00	0.83	6.24	22	31	34	39	37	53	73
Operating Cost of Revenue	-	-	0.83	6.24	22	31	34	39	37	53	73
Total Operating Expenses	70	130	186	473	464	477	478	503	439	450	528
Selling, General & Admin Expense	21	47	71	89	170	156	193	213	275	323	383
Research & Development Expense	48	77	105	149	286	308	272	277	152	109	136
Depreciation Expense	1.55	1.83	3.24	3.59	4.78	8.85	6.21	5.34	7.87	8.55	7.46
Other Operating Expenses / (Income)	-	-	-	0.00	0.00	-	0.26	0.00	-	0.00	0.00
Impairment Charge	-	-	0.00	465	-	0.00	0.00	6.62	1.13	0.00	1.70
Restructuring Charge	-0.06	0.02	0.07	-	-	-	-	0.00	0.00	9.19	0.00
Other Special Charges / (Income)	0.10	4.38	6.76	-234	3.30	3.14	6.51	1.08	2.58	0.00	0.00
Total Other Income / (Expense), net	-1.34	-1.68	-22	-7.14	-52	-27	-35	-30	-73	-54	-33
Interest Expense	1.48	1.58	5.40	17	19	22	32	37	64	50	46
Interest & Investment Income	0.22	0.93	1.60	4.10	10	3.23	0.51	3.02	7.08	5.41	3.32
Other Income / (Expense), net	-0.08	-1.03	-18	6.01	-43	-8.06	-2.90	4.18	-16	-9.44	10
Income Tax Expense	-1.11	-	-3.74	-165	0.48	2.60	8.91	-5.47	1.48	27	27
Basic Earnings per Share	($0.93)	($1.20)	($1.49)	($1.85)	($1.48)	($1.07)	($0.92)	($0.82)	($0.51)	($0.18)	($0.09)
Weighted Average Basic Shares Outstanding	74.44M	109.92M	134.40M	153.36M	240.42M	258.87M	271.42M	289.06M	295.16M	304.38M	308.36M
Diluted Earnings per Share	($0.93)	($1.20)	($1.49)	($1.85)	($1.48)	($1.07)	($0.92)	($0.82)	($0.51)	($0.18)	($0.09)
Weighted Average Diluted Shares Outstanding	74.44M	109.92M	134.40M	153.36M	240.42M	258.87M	271.42M	289.06M	295.16M	304.38M	308.36M
Weighted Average Basic & Diluted Shares Outstanding	74.44M	109.92M	134.40M	153.36M	240.42M	258.87M	280.03M	282.71M	295.38M	300.12M	314.00M

This table shows Amicus Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-43	-22	-34	-48	-16	-6.73	15	-22	-24	17	1.69
Consolidated Net Income / (Loss)	-43	-22	-34	-48	-16	-6.73	15	-22	-24	17	1.69
Net Income / (Loss) Continuing Operations	-43	-22	-34	-48	-16	-6.73	15	-22	-24	17	1.69
Total Pre-Tax Income	-41	-25	-32	-44	0.11	6.79	7.93	-18	-19	34	3.14
Total Operating Income	-19	-17	-3.69	-28	15	22	16	-7.95	-9.47	34	16
Total Gross Profit	85	94	104	97	115	128	135	114	139	150	159
Total Revenue	95	104	115	110	127	142	150	125	155	169	185
Operating Revenue	95	104	115	110	127	142	150	125	155	169	185
Total Cost of Revenue	9.11	9.95	11	14	11	13	15	12	15	19	27
Operating Cost of Revenue	9.11	9.95	11	14	11	13	15	12	15	19	27
Total Operating Expenses	104	111	108	125	100	107	119	122	149	115	143
Selling, General & Admin Expense	65	66	70	88	74	75	87	92	85	90	117
Research & Development Expense	35	41	35	28	25	26	30	28	61	23	24
Depreciation Expense	2.21	2.23	2.18	2.15	2.18	2.17	2.04	1.84	1.85	1.87	1.90
Total Other Income / (Expense), net	-22	-7.68	-28	-16	-15	-15	-8.04	-10	-9.71	0.01	-13
Interest Expense	12	13	27	12	13	13	12	11	12	12	11
Interest & Investment Income	1.74	1.47	1.67	1.54	1.37	1.08	1.42	0.81	0.84	0.83	0.83
Other Income / (Expense), net	-11	3.83	-2.63	-4.97	-3.72	-3.26	2.51	0.55	1.02	11	-2.21
Income Tax Expense	2.72	-3.13	2.18	4.84	16	14	-6.81	3.64	5.24	17	1.45
Weighted Average Basic Shares Outstanding	292.80M	295.76M	295.16M	302.90M	303.77M	304.69M	304.38M	307.69M	308.25M	308.47M	308.36M
Weighted Average Diluted Shares Outstanding	292.80M	295.76M	295.16M	302.90M	303.77M	304.69M	304.38M	307.69M	308.25M	310.43M	308.36M
Weighted Average Basic & Diluted Shares Outstanding	287.12M	293.25M	295.38M	296.20M	296.59M	298.81M	300.12M	307.93M	308.24M	308.53M	314.00M

This table details how cash moves in and out of Amicus Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	45	118	-136	30	64	20	83	-96	97	-33	0.60
Net Cash From Operating Activities	-100	-150	-214	-300	-250	-233	-202	-167	-69	-34	33
Net Cash From Continuing Operating Activities	-100	-150	-214	-300	-249	-233	-202	-167	-69	-34	33
Net Income / (Loss) Continuing Operations	-132	-200	-284	-349	-356	-277	-250	-237	-152	-56	-27
Consolidated Net Income / (Loss)	-132	-200	-284	-349	-356	-277	-250	-237	-152	-56	-27
Depreciation Expense	1.83	3.24	3.59	4.22	4.78	8.85	6.21	5.34	7.87	8.55	7.46
Amortization Expense	-	2.69	9.70	11	2.55	1.79	2.49	2.63	2.62	2.26	2.57
Non-Cash Adjustments To Reconcile Net Income	11	39	483	35	85	62	51	101	101	110	90
Changes in Operating Assets and Liabilities, net	19	4.81	-426	-1.43	15	-29	-12	-39	-29	-99	-40
Net Cash From Investing Activities	-145	-4.51	-171	-121	95	-14	79	92	98	-0.56	-46
Net Cash From Continuing Investing Activities	-145	-4.51	-171	-121	95	-14	79	92	98	-0.56	-46
Purchase of Property, Plant & Equipment	-4.82	-5.95	-4.53	-6.31	-20	-3.23	-3.88	-3.77	-7.44	-3.55	-3.30
Purchase of Investments	-290	-220	-490	-578	-384	-365	-341	-243	-92	-115	-94
Sale and/or Maturity of Investments	290	221	324	464	499	355	424	336	197	118	51
Net Cash From Financing Activities	291	273	247	451	218	263	212	-7.46	62	5.12	0.61
Net Cash From Continuing Financing Activities	291	273	247	451	218	263	212	-7.46	62	5.12	0.61
Repayment of Debt	-15	-80	-0.31	0.00	0.00	-155	0.00	0.00	-408	0.00	0.00
Issuance of Debt	50	273	0.00	147	0.00	386	0.00	0.00	387	0.00	0.00
Issuance of Common Equity	243	97	243	295	189	0.00	0.00	0.00	63	20	0.00
Other Financing Activities, net	15	-15	6.30	12	32	32	212	-7.46	19	-14	0.61
Other Net Changes in Cash	-	-	1.33	-	1.73	3.83	-	-15	6.31	-4.03	13
Cash Interest Paid	0.61	2.99	7.42	7.50	17	25	30	34	36	59	44
Cash Income Taxes Paid	-	-	-	1.06	0.69	10	20	1.61	8.53	8.21	15

This table details how cash moves in and out of Amicus Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Change in Cash & Equivalents	49	52	-16	-37	-0.44	24	-20	-32	-23	32	23
Net Cash From Operating Activities	-16	-38	3.46	-30	23	-23	-3.92	7.76	-27	36	16
Net Cash From Continuing Operating Activities	-16	-38	3.46	-30	23	-23	-3.92	7.76	-27	36	16
Net Income / (Loss) Continuing Operations	-43	-22	-34	-48	-16	-6.73	15	-22	-24	17	1.69
Consolidated Net Income / (Loss)	-43	-22	-34	-48	-16	-6.73	15	-22	-24	17	1.69
Depreciation Expense	2.21	2.23	2.18	2.15	2.18	2.17	2.04	1.84	1.85	1.87	1.90
Amortization Expense	0.69	0.72	0.54	0.53	0.56	0.57	0.60	0.61	0.63	0.66	0.68
Non-Cash Adjustments To Reconcile Net Income	29	11	20	38	25	25	22	21	24	26	19
Changes in Operating Assets and Liabilities, net	-4.52	-31	14	-22	11	-44	-44	6.01	-29	-9.89	-6.71
Net Cash From Investing Activities	50	36	-24	7.54	-22	34	-20	-33	-5.78	-1.30	-6.49
Net Cash From Continuing Investing Activities	50	36	-24	7.54	-22	34	-20	-33	-5.78	-1.30	-6.49
Purchase of Property, Plant & Equipment	-2.20	-1.57	-1.73	-1.81	-1.10	-0.36	-0.29	-0.21	-2.40	-0.38	-0.30
Purchase of Investments	-20	-17	-39	-30	-44	-4.91	-36	-39	-14	-18	-23
Sale and/or Maturity of Investments	72	54	16	39	23	40	16	6.16	11	17	17
Net Cash From Financing Activities	24	38	8.21	-13	-0.86	18	1.10	-12	-0.40	-1.32	14
Net Cash From Continuing Financing Activities	24	38	8.21	-13	-0.86	18	1.10	-12	-0.40	-1.32	14
Other Financing Activities, net	-0.53	1.06	29	-13	-0.86	-0.96	0.68	-12	-0.40	-1.32	14
Cash Interest Paid	12	12	0.64	12	12	24	11	11	11	11	11
Cash Income Taxes Paid	5.80	0.50	2.05	0.64	0.49	1.60	5.49	0.38	0.35	1.61	13

This table presents Amicus Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	908	1,037	627	790	850	887	905	724	778	785	950
Total Current Assets	217	340	392	551	520	579	597	424	483	505	676
Cash & Equivalents	69	187	49	80	143	163	245	149	247	214	214
Short-Term Investments	145	143	310	424	310	320	237	145	39	36	80
Accounts Receivable	-	1.30	9.46	22	33	47	53	66	88	101	115
Inventories, net	0.00	3.42	4.62	8.39	14	20	27	24	60	119	229
Prepaid Expenses	2.57	4.99	19	17	20	30	35	40	50	35	39
Plant, Property, & Equipment, net	6.18	9.82	9.06	11	48	44	42	31	32	29	27
Total Noncurrent Assets	686	687	226	227	282	263	266	270	263	251	247
Goodwill	198	198	198	198	198	198	198	198	198	198	198
Intangible Assets	487	487	23	23	23	23	23	23	20	17	14
Other Noncurrent Operating Assets	1.11	2.47	5.20	6.68	62	42	45	49	45	36	35
Total Liabilities & Shareholders' Equity	908	1,037	627	790	850	887	905	724	778	785	950
Total Liabilities	561	677	274	447	374	600	598	601	618	591	676
Total Current Liabilities	74	111	70	86	129	130	146	139	168	149	238
Accounts Payable	32	41	54	81	22	17	22	15	15	13	29
Accrued Expenses	-	-	-	-	100	97	98	94	144	127	200
Other Current Liabilities	-	-	-	-	7.19	6.87	7.41	8.55	8.32	8.46	8.74
Total Noncurrent Liabilities	487	566	204	361	245	470	452	462	450	442	438
Long-Term Debt	-	154	164	322	150	389	389	392	388	390	393
Other Noncurrent Operating Liabilities	233	216	19	23	82	69	52	70	62	52	45
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	348	360	353	343	476	286	307	123	160	194	274
Total Preferred & Common Equity	348	360	353	343	476	286	307	123	160	194	274
Total Common Equity	348	360	353	343	476	286	307	123	160	194	274
Common Stock	919	1,122	1,402	1,742	2,230	2,311	2,598	2,668	2,839	2,929	3,017
Retained Earnings	-580	-780	-1,064	-1,412	-1,769	-2,045	-2,296	-2,532	-2,684	-2,740	-2,767
Treasury Stock	-	-	-	-	-	-	-	-	-	0.00	-0.07
Accumulated Other Comprehensive Income / (Loss)	-0.12	2.05	-2.10	0.07	2.83	8.23	4.98	-12	5.24	5.10	24
Other Equity Adjustments	8.76	16	16	13	12	12	0.08	0.08	0.07	0.07	0.00

This table presents Amicus Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025
Total Assets	760	701	730	764	722	749	787	790	815	869
Total Current Assets	459	400	433	463	431	462	498	511	538	594
Cash & Equivalents	278	161	211	263	210	209	234	182	159	191
Short-Term Investments	77	107	54	17	30	51	16	69	72	73
Accounts Receivable	52	68	64	73	76	85	98	88	106	114
Inventories, net	13	27	51	57	61	81	115	132	155	178
Prepaid Expenses	38	37	52	53	54	35	35	39	46	38
Plant, Property, & Equipment, net	32	31	30	31	32	31	30	29	29	28
Total Noncurrent Assets	269	269	267	270	258	257	258	250	249	247
Goodwill	198	198	198	198	198	198	198	198	198	198
Intangible Assets	23	23	22	21	20	19	18	16	16	15
Other Noncurrent Operating Assets	48	49	47	51	41	40	42	36	35	34
Total Liabilities & Shareholders' Equity	760	701	730	764	722	749	787	790	815	869
Total Liabilities	627	598	619	631	591	617	608	596	611	638
Total Current Liabilities	165	138	159	169	142	168	158	153	168	199
Accounts Payable	12	25	14	23	9.21	32	13	14	14	19
Accrued Expenses	125	93	125	139	125	128	136	130	145	171
Other Current Liabilities	7.54	8.01	7.84	7.77	8.27	8.11	8.54	8.56	8.61	8.66
Total Noncurrent Liabilities	462	460	459	461	449	449	450	443	443	439
Long-Term Debt	391	393	393	394	388	389	389	391	391	392
Other Noncurrent Operating Liabilities	60	61	60	61	61	60	60	53	52	47
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	133	103	112	133	131	133	179	194	204	230
Total Preferred & Common Equity	133	103	112	133	131	133	179	194	204	230
Total Common Equity	133	103	112	133	131	133	179	194	204	230
Common Stock	2,648	2,695	2,736	2,790	2,856	2,872	2,909	2,943	2,960	2,977
Retained Earnings	-2,477	-2,585	-2,629	-2,650	-2,732	-2,748	-2,755	-2,762	-2,786	-2,769
Treasury Stock	-	-	-	-	-	-	-	-0.07	-0.07	-0.07
Accumulated Other Comprehensive Income / (Loss)	-39	-6.74	4.16	-6.77	6.64	8.79	25	13	31	23
Other Equity Adjustments	0.08	0.08	0.07	0.07	0.07	0.07	0.07	0.00	0.00	0.00

This table displays calculated financial ratios and metrics derived from Amicus Therapeutics' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-100.00%	0.00%	644.86%	0.00%	0.00%	43.16%	17.11%	7.76%	21.30%	32.29%	20.05%
EBITDA Growth	-92.82%	-49.69%	-117.82%	23.83%	-5.59%	28.11%	17.91%	0.33%	58.69%	131.77%	102.19%
EBIT Growth	-91.15%	-52.12%	-118.00%	22.67%	-3.01%	26.56%	17.93%	0.66%	55.23%	116.58%	178.80%
NOPAT Growth	-89.86%	-39.45%	-143.00%	17.66%	7.52%	18.76%	16.42%	-2.75%	63.60%	132.22%	-26,826.72%
Net Income Growth	-91.68%	-51.41%	-41.97%	-22.88%	-2.12%	22.32%	9.53%	5.55%	35.92%	62.99%	51.68%
EPS Growth	-29.03%	-24.17%	-24.16%	0.00%	0.00%	27.70%	14.02%	10.87%	37.80%	64.71%	50.00%
Operating Cash Flow Growth	-93.81%	-49.94%	-42.32%	-40.37%	16.52%	6.84%	13.20%	17.74%	58.52%	50.95%	197.80%
Free Cash Flow Firm Growth	-814.54%	55.72%	-56.33%	-8.64%	-0.77%	10.88%	12.24%	10.29%	53.85%	24.73%	-8,438.43%
Invested Capital Growth	764.81%	10.87%	-30.58%	-3.81%	7.91%	16.21%	15.83%	4.17%	7.81%	27.64%	11.72%
Revenue Q/Q Growth	-100.00%	133.10%	47.53%	0.00%	0.00%	6.22%	3.94%	1.84%	7.25%	7.01%	5.93%
EBITDA Q/Q Growth	-18.47%	-10.91%	-3.55%	-1.30%	-7.56%	8.05%	-0.23%	5.30%	40.13%	1,617.54%	-8.30%
EBIT Q/Q Growth	-18.39%	-12.43%	-3.87%	-1.44%	-6.55%	7.26%	0.29%	5.18%	36.98%	264.89%	-9.92%
NOPAT Q/Q Growth	-17.46%	-2.26%	-5.31%	-0.55%	-6.87%	8.92%	-3.67%	12.32%	33.35%	377.19%	-4,925.19%
Net Income Q/Q Growth	-20.12%	-8.55%	-3.86%	-2.61%	-3.38%	6.21%	-4.98%	10.38%	12.69%	46.41%	-92.80%
EPS Q/Q Growth	-11.11%	-3.47%	-1.09%	0.00%	6.92%	4.46%	-2.22%	10.87%	13.56%	47.06%	-125.00%
Operating Cash Flow Q/Q Growth	-26.54%	2.54%	-24.05%	3.96%	1.12%	3.32%	-11.38%	-6.56%	54.94%	-27.81%	155.43%
Free Cash Flow Firm Q/Q Growth	-18.53%	19.98%	-17.64%	10.55%	-8.26%	2.57%	-6.89%	-18.97%	47.50%	19.06%	-3,438.86%
Invested Capital Q/Q Growth	19.04%	-2.36%	9.14%	-7.85%	-5.53%	0.75%	3.44%	28.49%	6.00%	4.91%	4.13%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	83.20%	83.11%	0.00%	87.95%	88.10%	88.72%	88.28%	90.65%	89.98%	88.50%
EBITDA Margin	0.00%	-3,913.96%	-1,144.55%	0.00%	-186.55%	-93.69%	-65.67%	-60.74%	-20.69%	4.97%	8.37%
Operating Margin	0.00%	-3,668.62%	-1,196.82%	0.00%	-166.84%	-94.68%	-67.57%	-64.43%	-19.33%	4.71%	5.17%
EBIT Margin	0.00%	-4,033.58%	-1,180.55%	0.00%	-190.57%	-97.76%	-68.52%	-63.16%	-23.31%	2.92%	6.79%
Profit (Net Income) Margin	0.00%	-4,034.73%	-769.03%	0.00%	-195.56%	-106.12%	-81.98%	-71.85%	-37.96%	-10.62%	-4.27%
Tax Burden Percent	100.00%	98.17%	63.24%	99.97%	100.13%	100.95%	103.69%	97.74%	100.99%	195.11%	-14,193.72%
Interest Burden Percent	100.49%	101.90%	103.01%	103.54%	102.48%	107.53%	115.39%	116.40%	161.23%	-186.30%	0.44%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	14,293.72%
Return on Invested Capital (ROIC)	0.00%	-55.70%	-151.95%	0.00%	-127.56%	-92.35%	-66.53%	-62.39%	-21.42%	5.84%	-1,315.47%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	2.28%	-168.56%	0.00%	-68.44%	-38.81%	66.45%	-448.95%	-109.50%	-54.96%	2,551.71%
Return on Net Nonoperating Assets (RNNOA)	0.00%	-0.81%	72.29%	0.00%	40.56%	19.76%	-17.83%	-47.54%	-85.62%	-37.52%	1,303.89%
Return on Equity (ROE)	-56.22%	-56.51%	-79.66%	-100.32%	-86.99%	-72.59%	-84.37%	-109.93%	-107.04%	-31.68%	-11.58%
Cash Return on Invested Capital (CROIC)	-157.16%	-66.01%	-115.85%	-136.72%	-135.16%	-107.34%	-81.20%	-66.48%	-28.94%	-18.44%	-1,326.54%
Operating Return on Assets (OROA)	0.00%	-20.56%	-52.41%	0.00%	-42.35%	-29.37%	-23.37%	-25.53%	-12.40%	1.98%	4.96%
Return on Assets (ROA)	0.00%	-20.57%	-34.14%	0.00%	-43.46%	-31.88%	-27.96%	-29.04%	-20.18%	-7.18%	-3.13%
Return on Common Equity (ROCE)	-56.22%	-56.51%	-79.66%	-100.32%	-86.99%	-72.59%	-84.37%	-109.93%	-107.04%	-31.68%	-11.58%
Return on Equity Simple (ROE_SIMPLE)	-37.98%	-55.54%	-80.49%	-101.77%	-74.80%	-96.67%	-81.49%	-192.26%	-94.64%	-28.91%	0.00%
Net Operating Profit after Tax (NOPAT)	-91	-127	-309	-230	-213	-173	-145	-148	-54	17	-4,654
NOPAT Margin	0.00%	-2,568.03%	-837.77%	0.00%	-116.79%	-66.27%	-47.30%	-45.10%	-13.53%	3.30%	-733.82%
Net Nonoperating Expense Percent (NNEP)	-28.56%	-57.99%	16.61%	-64.52%	-59.12%	-53.54%	-132.98%	386.56%	88.08%	60.80%	-3,867.18%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-27.68%	-9.86%	2.98%	-697.85%
Cost of Revenue to Revenue	0.00%	16.80%	16.89%	0.00%	12.05%	11.90%	11.28%	11.72%	9.35%	10.02%	11.50%
SG&A Expenses to Revenue	0.00%	1,435.07%	240.11%	0.00%	93.21%	59.95%	63.08%	64.71%	68.93%	61.21%	60.47%
R&D to Revenue	0.00%	2,113.61%	404.31%	0.00%	157.15%	118.23%	89.05%	84.04%	38.16%	20.70%	21.42%
Operating Expenses to Revenue	0.00%	3,751.82%	1,279.93%	0.00%	254.78%	182.78%	156.37%	152.70%	109.99%	85.27%	83.33%
Earnings before Interest and Taxes (EBIT)	-131	-200	-436	-337	-347	-255	-209	-208	-93	15	43
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-130	-194	-423	-322	-340	-244	-201	-200	-83	26	53
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.48	1.96	6.78	0.00	5.21	21.01	10.47	27.88	25.98	14.51	16.02
Price to Tangible Book Value (P/TBV)	0.00	0.00	18.12	0.00	9.71	91.75	37.17	0.00	0.00	0.00	70.26
Price to Revenue (P/Rev)	0.00	142.67	64.79	0.00	13.62	23.06	10.53	10.42	10.42	5.33	6.93
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	4.79	2.44	13.22	0.00	12.58	29.47	13.49	14.62	16.28	8.84	12.03
Enterprise Value to Revenue (EV/Rev)	0.00	118.51	59.75	0.00	11.95	22.74	10.29	10.78	10.67	5.59	7.08
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	112.59	84.67
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	191.44	104.40
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	169.69	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	135.55
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.12	0.58	0.49	0.94	0.31	1.39	1.33	3.36	2.42	2.01	1.43
Long-Term Debt to Equity	0.00	0.43	0.47	0.94	0.31	1.36	1.27	3.19	2.42	2.01	1.43
Financial Leverage	-0.61	-0.35	-0.43	-0.53	-0.59	-0.51	-0.27	0.11	0.78	0.68	0.51
Leverage Ratio	2.38	2.75	2.33	2.04	2.00	2.28	3.02	3.79	5.30	4.41	3.70
Compound Leverage Factor	2.39	2.80	2.40	2.11	2.05	2.45	3.48	4.41	8.55	-8.22	0.02
Debt to Total Capital	10.64%	36.89%	32.84%	48.41%	23.89%	58.16%	57.05%	77.06%	70.77%	66.78%	58.88%
Short-Term Debt to Total Capital	10.64%	9.83%	1.60%	0.00%	0.00%	1.30%	2.64%	3.99%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	27.06%	31.25%	48.41%	23.89%	56.86%	54.41%	73.07%	70.77%	66.78%	58.88%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	89.36%	63.11%	67.16%	51.59%	76.11%	41.84%	42.95%	22.94%	29.23%	33.22%	41.12%
Debt to EBITDA	-0.32	-1.09	-0.41	-1.00	-0.44	-1.63	-2.03	-2.07	-4.70	14.86	7.40
Net Debt to EBITDA	1.33	0.62	0.44	0.57	0.89	0.35	0.37	-0.60	-1.23	5.34	1.87
Long-Term Debt to EBITDA	0.00	-0.80	-0.39	-1.00	-0.44	-1.59	-1.94	-1.96	-4.70	14.86	7.40
Debt to NOPAT	-0.45	-1.65	-0.56	-1.40	-0.70	-2.30	-2.83	-2.78	-7.18	22.40	-0.08
Net Debt to NOPAT	1.89	0.94	0.60	0.79	1.42	0.49	0.51	-0.81	-1.88	8.05	-0.02
Long-Term Debt to NOPAT	0.00	-1.21	-0.53	-1.40	-0.70	-2.25	-2.69	-2.64	-7.18	22.40	-0.08
Altman Z-Score	0.11	-0.79	1.24	-3.20	0.49	2.74	-0.15	-1.49	-0.18	-0.75	1.19
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.94	3.06	5.60	6.40	4.04	4.47	4.09	3.05	2.88	3.39	2.84
Quick Ratio	2.91	2.99	5.25	6.11	3.77	4.09	3.67	2.59	2.23	2.36	1.72
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-341	-151	-236	-224	-226	-201	-176	-158	-73	-55	-4,693
Operating Cash Flow to CapEx	-2,078.87%	-2,523.05%	-4,721.50%	-4,755.15%	-1,251.33%	-7,229.32%	-5,213.47%	-46,922.54%	-928.64%	-953.87%	1,005.61%
Free Cash Flow to Firm to Interest Expense	-215.92	-27.95	-13.68	-9.99	-11.95	-8.96	-5.43	-4.26	-1.14	-1.11	-101.67
Operating Cash Flow to Interest Expense	-63.46	-27.82	-12.40	-13.39	-13.27	-10.40	-6.24	-4.49	-1.08	-0.68	0.72
Operating Cash Flow Less CapEx to Interest Expense	-66.51	-28.92	-12.66	-13.67	-14.33	-10.55	-6.36	-4.50	-1.19	-0.75	0.65
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.01	0.04	0.00	0.22	0.30	0.34	0.40	0.53	0.68	0.73
Accounts Receivable Turnover	0.00	0.00	6.86	0.00	6.60	6.51	6.14	5.54	5.19	5.60	5.86
Inventory Turnover	0.00	0.00	1.55	0.00	1.96	1.85	1.49	1.52	0.89	0.59	0.42
Fixed Asset Turnover	0.00	0.62	3.91	0.00	6.17	5.70	7.08	8.99	12.79	17.31	22.45
Accounts Payable Turnover	0.00	0.02	0.13	0.00	0.43	1.60	1.79	2.09	2.45	3.77	3.51
Days Sales Outstanding (DSO)	0.00	0.00	53.21	0.00	55.33	56.11	59.49	65.89	70.30	65.20	62.27
Days Inventory Outstanding (DIO)	0.00	0.00	235.27	0.00	186.39	197.51	245.55	239.40	408.32	615.23	869.85
Days Payable Outstanding (DPO)	0.00	16,042.47	2,777.24	0.00	850.45	228.01	204.26	174.59	149.29	96.75	104.04
Cash Conversion Cycle (CCC)	0.00	-16,042.47	-2,488.76	0.00	-608.73	25.61	100.78	130.70	329.33	583.68	828.08
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	217	240	167	161	173	201	233	243	262	334	373
Invested Capital Turnover	0.00	0.02	0.18	0.00	1.09	1.39	1.41	1.38	1.58	1.77	1.79
Increase / (Decrease) in Invested Capital	249	24	-74	-6.36	13	28	32	9.73	19	72	39
Enterprise Value (EV)	1,039	588	2,207	-182	2,179	5,932	3,144	3,550	4,263	2,955	4,493
Market Capitalization	1,212	707	2,393	0.00	2,482	6,017	3,218	3,430	4,161	2,815	4,394
Book Value per Share	$2.78	$2.53	$2.12	$0.00	$1.87	$1.10	$1.10	$0.44	$0.55	$0.65	$0.89
Tangible Book Value per Share	($2.70)	($2.28)	$0.79	$0.00	$1.00	$0.25	$0.31	($0.35)	($0.20)	($0.07)	$0.20
Total Capital	389	571	525	665	626	685	716	536	548	584	667
Total Debt	41	211	173	322	150	398	408	413	388	390	393
Total Long-Term Debt	0.00	154	164	322	150	389	389	392	388	390	393
Net Debt	-173	-120	-186	-182	-303	-85	-74	120	102	140	99
Capital Expenditures (CapEx)	4.82	5.95	4.53	6.31	20	3.23	3.88	0.36	7.44	3.55	3.30
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-30	-45	-28	-39	-61	-25	-13	13	29	106	145
Debt-free Net Working Capital (DFNWC)	184	285	330	465	391	459	470	306	315	356	438
Net Working Capital (NWC)	143	229	322	465	391	450	451	285	315	356	438
Net Nonoperating Expense (NNE)	41	73	-25	119	144	104	106	88	98	74	-4,627
Net Nonoperating Obligations (NNO)	-131	-120	-186	-182	-303	-85	-74	120	102	140	99
Total Depreciation and Amortization (D&A)	1.83	5.93	13	15	7.32	11	8.70	7.98	10	11	10
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-910.55%	-76.46%	0.00%	-33.74%	-9.42%	-4.17%	3.83%	7.30%	20.08%	22.83%
Debt-free Net Working Capital to Revenue	0.00%	5,752.44%	894.46%	0.00%	214.70%	175.82%	153.76%	93.01%	78.97%	67.39%	69.12%
Net Working Capital to Revenue	0.00%	4,620.92%	871.72%	0.00%	214.70%	172.41%	147.57%	86.50%	78.97%	67.39%	69.12%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.20)	($1.49)	($1.85)	$0.00	($1.48)	($1.07)	($0.92)	($0.82)	($0.51)	($0.18)	($0.09)
Adjusted Weighted Average Basic Shares Outstanding	125.21M	194.82M	186.89M	0.00	257.24M	264.32M	271.42M	289.06M	295.16M	304.38M	308.36M
Adjusted Diluted Earnings per Share	($1.20)	($1.49)	($1.85)	$0.00	($1.48)	($1.07)	($0.92)	($0.82)	($0.51)	($0.18)	($0.09)
Adjusted Weighted Average Diluted Shares Outstanding	125.21M	194.82M	186.89M	0.00	257.24M	264.32M	271.42M	289.06M	295.16M	304.38M	308.36M
Adjusted Basic & Diluted Earnings per Share	($1.20)	($1.49)	($1.85)	($1.88)	($1.48)	($1.07)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	109.92M	134.40M	153.36M	185.79M	240.42M	258.87M	280.03M	282.71M	295.38M	300.12M	314.00M
Normalized Net Operating Profit after Tax (NOPAT)	-88	-123	-148	-228	-211	-171	-140	-143	-51	24	24
Normalized NOPAT Margin	0.00%	-2,471.62%	-399.72%	0.00%	-115.52%	-65.43%	-45.81%	-43.46%	-12.88%	4.51%	3.81%
Pre Tax Income Margin	0.00%	-4,110.15%	-1,216.14%	0.00%	-195.30%	-105.12%	-79.06%	-73.52%	-37.59%	-5.44%	0.03%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-83.31	-37.05	-25.29	-15.05	-18.40	-11.37	-6.45	-5.60	-1.45	0.31	0.93
NOPAT to Interest Expense	-57.86	-23.59	-17.95	-10.27	-11.28	-7.71	-4.45	-4.00	-0.84	0.35	-100.82
EBIT Less CapEx to Interest Expense	-86.37	-38.15	-25.55	-15.33	-19.46	-11.52	-6.57	-5.61	-1.57	0.24	0.86
NOPAT Less CapEx to Interest Expense	-60.91	-24.69	-18.21	-10.55	-12.34	-7.85	-4.57	-4.01	-0.96	0.28	-100.90
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Amicus Therapeutics' official financial filings.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	17.06%	26.70%	30.63%	27.97%	34.04%	36.73%	30.09%	13.45%	22.12%	19.46%	23.72%
EBITDA Growth	47.69%	43.89%	93.89%	28.40%	152.08%	306.43%	686.17%	83.47%	-142.72%	125.58%	-22.75%
EBIT Growth	44.21%	34.72%	89.63%	25.41%	137.80%	239.47%	392.34%	77.35%	-175.19%	145.47%	-25.64%
NOPAT Growth	68.88%	49.70%	91.28%	26.34%	-16,377.37%	-80.26%	1,248.02%	71.31%	99.70%	180.56%	-71.10%
Net Income Growth	30.45%	35.18%	39.42%	8.53%	63.69%	68.81%	143.55%	55.21%	-55.57%	357.19%	-88.53%
EPS Growth	28.57%	41.67%	42.11%	11.11%	66.67%	71.43%	145.45%	56.25%	-60.00%	400.00%	0.00%
Operating Cash Flow Growth	-1.71%	-229.84%	104.28%	-64.34%	240.65%	40.10%	-213.24%	126.13%	-216.90%	255.24%	515.04%
Free Cash Flow Firm Growth	-3,317.40%	-651.19%	45.23%	-90.06%	-3,065.39%	-33.08%	-98.12%	-2.89%	94.97%	75.60%	28.40%
Invested Capital Growth	28.40%	30.68%	7.81%	16.07%	3.60%	28.97%	27.64%	19.40%	39.49%	12.56%	11.72%
Revenue Q/Q Growth	9.54%	9.52%	11.19%	-4.07%	14.73%	11.72%	5.79%	-16.34%	23.50%	9.29%	9.55%
EBITDA Q/Q Growth	35.89%	61.88%	64.83%	-732.93%	146.64%	51.09%	-0.12%	-123.49%	-20.53%	897.86%	-65.80%
EBIT Q/Q Growth	32.09%	55.68%	52.08%	-417.20%	134.42%	63.52%	0.43%	-140.06%	-14.28%	633.82%	-69.58%
NOPAT Q/Q Growth	49.89%	9.74%	78.31%	-650.84%	-11,110.39%	99.01%	238.12%	-118.76%	-19.14%	360.92%	-50.45%
Net Income Q/Q Growth	18.33%	50.09%	-56.85%	-43.07%	67.58%	57.13%	319.04%	-247.13%	-12.61%	170.87%	-90.23%
EPS Q/Q Growth	16.67%	53.33%	-57.14%	-45.45%	68.75%	60.00%	350.00%	-240.00%	-14.29%	175.00%	0.00%
Operating Cash Flow Q/Q Growth	10.71%	-137.69%	109.02%	-958.73%	176.41%	-201.23%	82.95%	298.11%	-441.92%	234.43%	-54.42%
Free Cash Flow Firm Q/Q Growth	-125.76%	-1.30%	69.16%	-169.50%	-3,659.99%	95.74%	54.09%	-39.97%	-83.78%	79.34%	-34.71%
Invested Capital Q/Q Growth	4.78%	-2.10%	6.00%	6.74%	-6.47%	21.87%	4.91%	-0.15%	9.27%	-1.66%	4.13%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	90.36%	90.39%	90.16%	87.71%	91.11%	90.62%	90.09%	90.66%	90.16%	88.49%	85.67%
EBITDA Margin	-28.43%	-9.89%	-3.13%	-27.18%	11.05%	14.94%	14.10%	-3.96%	-3.86%	28.21%	8.81%
Operating Margin	-19.96%	-16.45%	-3.21%	-25.11%	11.82%	15.30%	10.67%	-6.35%	-6.12%	20.27%	8.61%
EBIT Margin	-31.49%	-12.74%	-5.49%	-29.61%	8.88%	13.00%	12.34%	-5.91%	-5.47%	26.71%	7.42%
Profit (Net Income) Margin	-45.75%	-20.85%	-29.41%	-43.86%	-12.39%	-4.75%	9.85%	-17.31%	-15.79%	10.24%	0.91%
Tax Burden Percent	106.70%	87.34%	106.90%	111.10%	-14,534.26%	-99.17%	185.77%	120.18%	127.31%	50.49%	53.77%
Interest Burden Percent	136.14%	187.30%	500.95%	133.33%	0.96%	36.88%	42.94%	243.79%	226.75%	75.90%	22.88%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	14,634.26%	199.17%	-85.77%	0.00%	0.00%	49.51%	46.23%
Return on Invested Capital (ROIC)	-21.82%	-19.66%	-3.55%	-28.61%	-3,046.53%	-26.50%	35.13%	-7.87%	-7.82%	18.10%	8.30%
ROIC Less NNEP Spread (ROIC-NNEP)	-58.49%	-31.02%	-31.78%	-48.83%	-1,444.45%	-14.86%	22.78%	-19.03%	-20.12%	18.10%	2.54%
Return on Net Nonoperating Assets (RNNOA)	-33.62%	-19.86%	-24.85%	-60.08%	-1,595.36%	-12.07%	15.55%	-16.96%	-17.28%	11.85%	1.30%
Return on Equity (ROE)	-55.44%	-39.53%	-28.41%	-88.69%	-4,641.89%	-38.57%	50.69%	-24.83%	-25.10%	29.95%	9.60%
Cash Return on Invested Capital (CROIC)	-66.25%	-63.80%	-28.94%	-32.98%	-12.66%	-24.01%	-18.44%	-7.49%	-28.46%	-39.17%	-1,326.54%
Operating Return on Assets (OROA)	-14.43%	-6.23%	-2.92%	-17.63%	5.47%	8.28%	8.34%	-4.25%	-3.99%	19.32%	5.42%
Return on Assets (ROA)	-20.95%	-10.19%	-15.64%	-26.12%	-7.63%	-3.03%	6.66%	-12.44%	-11.52%	7.40%	0.67%
Return on Common Equity (ROCE)	-55.44%	-39.53%	-28.41%	-88.69%	-4,641.89%	-38.57%	50.69%	-24.83%	-25.10%	29.95%	9.60%
Return on Equity Simple (ROE_SIMPLE)	-166.08%	-130.30%	0.00%	-112.53%	-90.20%	-58.54%	0.00%	-15.18%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-13	-12	-2.58	-19	-2,175	-21	30	-5.57	-6.63	17	8.57
NOPAT Margin	-13.97%	-11.51%	-2.25%	-17.58%	-1,717.34%	-15.18%	19.82%	-4.44%	-4.29%	10.24%	4.63%
Net Nonoperating Expense Percent (NNEP)	36.67%	11.35%	28.23%	20.22%	-1,602.08%	-11.64%	12.35%	11.16%	12.30%	0.00%	5.75%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-0.47%	-	-	-	5.08%	-0.95%	-1.11%	2.78%	1.29%
Cost of Revenue to Revenue	9.64%	9.61%	9.84%	12.29%	8.89%	9.38%	9.91%	9.34%	9.84%	11.51%	14.33%
SG&A Expenses to Revenue	69.23%	63.43%	61.03%	79.73%	58.09%	53.07%	57.89%	73.32%	54.65%	53.26%	63.21%
R&D to Revenue	37.19%	39.33%	30.44%	25.66%	19.49%	18.49%	20.17%	22.23%	39.34%	13.85%	12.82%
Operating Expenses to Revenue	110.31%	106.84%	93.59%	112.82%	79.29%	75.31%	79.42%	97.01%	96.29%	68.22%	77.06%
Earnings before Interest and Taxes (EBIT)	-30	-13	-6.32	-33	11	18	18	-7.40	-8.46	45	14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-27	-10	-3.60	-30	14	21	21	-4.96	-5.98	48	16
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	32.03	26.20	25.98	26.43	22.17	17.71	14.51	12.65	8.64	10.54	16.02
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	135.82	70.26
Price to Revenue (P/Rev)	10.20	9.38	10.42	8.16	6.45	6.42	5.33	4.51	3.09	4.06	6.93
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	14.72	14.60	16.28	12.89	11.73	10.38	8.84	7.76	5.28	7.13	12.03
Enterprise Value to Revenue (EV/Rev)	10.60	9.68	10.67	8.51	6.73	6.70	5.59	4.77	3.37	4.27	7.08
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	2,164.48	112.59	50.48	61.46	44.19	84.67
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	191.44	63.58	91.61	53.53	104.40
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	906.34	169.69	82.85	136.10	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	726.86	0.00	197.06	135.55
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	3.64	2.96	2.42	2.97	2.93	2.18	2.01	2.02	1.92	1.70	1.43
Long-Term Debt to Equity	3.53	2.96	2.42	2.97	2.93	2.18	2.01	2.02	1.92	1.70	1.43
Financial Leverage	0.57	0.64	0.78	1.23	1.10	0.81	0.68	0.89	0.86	0.65	0.51
Leverage Ratio	5.37	5.73	5.30	6.10	6.06	4.97	4.41	4.66	4.65	4.04	3.70
Compound Leverage Factor	7.31	10.74	26.57	8.13	0.06	1.83	1.89	11.37	10.53	3.07	0.85
Debt to Total Capital	78.46%	74.73%	70.77%	74.82%	74.59%	68.53%	66.78%	66.87%	65.70%	62.98%	58.88%
Short-Term Debt to Total Capital	2.51%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	75.95%	74.73%	70.77%	74.82%	74.59%	68.53%	66.78%	66.87%	65.70%	62.98%	58.88%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	21.54%	25.27%	29.23%	25.18%	25.41%	31.47%	33.22%	33.13%	34.30%	37.02%	41.12%
Debt to EBITDA	-2.78	-2.86	-4.70	-5.49	-13.03	254.90	14.86	7.62	12.50	6.77	7.40
Net Debt to EBITDA	-0.96	-0.82	-1.23	-2.10	-4.32	91.45	5.34	2.73	5.12	2.21	1.87
Long-Term Debt to EBITDA	-2.69	-2.86	-4.70	-5.49	-13.03	254.90	14.86	7.62	12.50	6.77	7.40
Debt to NOPAT	-4.38	-4.86	-7.18	-8.24	-16.60	106.74	22.40	12.50	27.67	-4.23	-0.08
Net Debt to NOPAT	-1.52	-1.40	-1.88	-3.16	-5.50	38.29	8.05	4.48	11.34	-1.38	-0.02
Long-Term Debt to NOPAT	-4.24	-4.86	-7.18	-8.24	-16.60	106.74	22.40	12.50	27.67	-4.23	-0.08
Altman Z-Score	-0.78	-0.64	0.18	-0.88	-1.15	-0.55	-0.73	-1.23	-1.84	-0.77	1.09
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.72	2.73	2.88	3.03	2.75	3.15	3.39	3.34	3.21	2.99	2.84
Quick Ratio	2.07	2.09	2.23	2.22	2.05	2.20	2.36	2.22	2.01	1.90	1.72
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-69	-70	-22	-58	-2,184	-93	-43	-60	-110	-23	-31
Operating Cash Flow to CapEx	-732.65%	-2,450.29%	199.77%	-1,639.70%	2,066.58%	-6,452.53%	-1,359.72%	3,659.43%	-1,103.87%	9,335.08%	5,435.79%
Free Cash Flow to Firm to Interest Expense	-5.52	-5.38	-0.81	-4.67	-174.59	-7.33	-3.57	-5.22	-9.50	-1.94	-2.68
Operating Cash Flow to Interest Expense	-1.29	-2.95	0.13	-2.39	1.81	-1.81	-0.33	0.68	-2.29	3.05	1.42
Operating Cash Flow Less CapEx to Interest Expense	-1.47	-3.07	0.06	-2.53	1.73	-1.84	-0.35	0.66	-2.50	3.01	1.40
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.46	0.49	0.53	0.60	0.62	0.64	0.68	0.72	0.73	0.72	0.73
Accounts Receivable Turnover	6.03	5.93	5.19	5.86	6.12	5.76	5.60	6.59	5.98	5.65	5.86
Inventory Turnover	1.08	1.01	0.89	1.00	0.69	0.57	0.59	0.53	0.47	0.42	0.42
Fixed Asset Turnover	10.97	11.72	12.79	13.27	14.84	16.05	17.31	17.77	19.12	20.58	22.45
Accounts Payable Turnover	2.12	2.01	2.45	2.57	2.02	2.70	3.77	4.32	2.40	3.76	3.51
Days Sales Outstanding (DSO)	60.53	61.57	70.30	62.32	59.63	63.36	65.20	55.36	61.04	64.60	62.27
Days Inventory Outstanding (DIO)	339.22	362.09	408.32	364.42	525.36	636.04	615.23	690.25	783.31	874.27	869.85
Days Payable Outstanding (DPO)	171.98	181.54	149.29	141.91	180.45	135.26	96.75	84.55	152.39	97.14	104.04
Cash Conversion Cycle (CCC)	227.77	242.12	329.33	284.84	404.55	564.15	583.68	661.06	691.96	841.73	828.08
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	252	247	262	279	261	319	334	334	365	359	373
Invested Capital Turnover	1.56	1.71	1.58	1.63	1.77	1.75	1.77	1.77	1.82	1.77	1.79
Increase / (Decrease) in Invested Capital	56	58	19	39	9.09	72	72	54	103	40	39
Enterprise Value (EV)	3,715	3,605	4,263	3,603	3,067	3,307	2,955	2,589	1,925	2,557	4,493
Market Capitalization	3,574	3,491	4,161	3,454	2,938	3,168	2,815	2,449	1,764	2,429	4,394
Book Value per Share	$0.39	$0.46	$0.55	$0.43	$0.45	$0.60	$0.65	$0.64	$0.66	$0.75	$0.89
Tangible Book Value per Share	($0.38)	($0.30)	($0.20)	($0.29)	($0.28)	($0.12)	($0.07)	($0.07)	($0.03)	$0.06	$0.20
Total Capital	518	527	548	519	521	568	584	584	596	622	667
Total Debt	406	394	388	388	389	389	390	391	391	392	393
Total Long-Term Debt	393	394	388	388	389	389	390	391	391	392	393
Net Debt	141	114	102	149	129	140	140	140	160	128	99
Capital Expenditures (CapEx)	2.20	1.57	1.73	1.81	1.10	0.36	0.29	0.21	2.40	0.38	0.30
Debt-free, Cash-free Net Working Capital (DFCFNWC)	21	14	29	50	34	91	106	107	139	131	145
Debt-free Net Working Capital (DFNWC)	287	294	315	289	294	340	356	358	370	395	438
Net Working Capital (NWC)	274	294	315	289	294	340	356	358	370	395	438
Net Nonoperating Expense (NNE)	30	9.66	31	29	-2,160	-15	15	16	18	-0.00	6.88
Net Nonoperating Obligations (NNO)	141	114	102	149	129	140	140	140	160	128	99
Total Depreciation and Amortization (D&A)	2.90	2.95	2.72	2.69	2.74	2.74	2.64	2.44	2.48	2.53	2.57
Debt-free, Cash-free Net Working Capital to Revenue	5.98%	3.63%	7.30%	11.70%	7.37%	18.35%	20.08%	19.76%	24.40%	21.93%	22.83%
Debt-free Net Working Capital to Revenue	81.75%	78.90%	78.97%	68.28%	64.44%	68.94%	67.39%	65.90%	64.84%	66.00%	69.12%
Net Working Capital to Revenue	78.04%	78.90%	78.97%	68.28%	64.44%	68.94%	67.39%	65.90%	64.84%	66.00%	69.12%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.15)	($0.07)	($0.11)	($0.16)	($0.05)	($0.02)	$0.05	($0.07)	($0.08)	$0.06	$0.00
Adjusted Weighted Average Basic Shares Outstanding	292.80M	295.76M	295.16M	302.90M	303.77M	304.69M	304.38M	307.69M	308.25M	308.47M	308.36M
Adjusted Diluted Earnings per Share	($0.15)	($0.07)	($0.11)	($0.16)	($0.05)	($0.02)	$0.05	($0.07)	($0.08)	$0.06	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	292.80M	295.76M	295.16M	302.90M	303.77M	304.69M	304.38M	307.69M	308.25M	310.43M	308.36M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	287.12M	293.25M	295.38M	296.20M	296.59M	298.81M	300.12M	307.93M	308.24M	308.53M	314.00M
Normalized Net Operating Profit after Tax (NOPAT)	-12	-11	-2.58	-15	10	17	11	-5.57	-5.44	17	8.57
Normalized NOPAT Margin	-12.88%	-10.16%	-2.25%	-13.74%	8.27%	12.27%	7.47%	-4.44%	-3.52%	10.24%	4.63%
Pre Tax Income Margin	-42.87%	-23.87%	-27.51%	-39.48%	0.09%	4.79%	5.30%	-14.41%	-12.40%	20.27%	1.70%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-2.38	-1.02	-0.24	-2.63	0.90	1.45	1.55	-0.65	-0.73	3.86	1.20
NOPAT to Interest Expense	-1.06	-0.92	-0.10	-1.56	-173.86	-1.69	2.48	-0.49	-0.57	1.48	0.75
EBIT Less CapEx to Interest Expense	-2.56	-1.14	-0.30	-2.77	0.81	1.42	1.52	-0.66	-0.94	3.82	1.18
NOPAT Less CapEx to Interest Expense	-1.23	-1.04	-0.16	-1.71	-173.95	-1.72	2.46	-0.50	-0.78	1.44	0.72
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Amicus Therapeutics (NASDAQ:FOLD) shows a growing top line in 2025, with improving cash generation and a firmer liquidity position, though profitability remains a work in progress. The company continues to invest heavily in R&D and SG&A, and carries a meaningful long‑term debt load. Here are the key themes, based on quarterly results from the last four years.

Revenue growth in 2025: Q4 2025 revenue is $185.2M, up from Q4 2024’s $149.7M (roughly +23%).
High gross margins persist: Q4 2025 gross profit is $158.7M on $185.2M in revenue, about 85.8% gross margin.
Cash flow from operations turning more positive: Q3 2025 CFO was $35.66M and Q4 2025 CFO was $16.25M, signaling improving cash generation.
Early signs of profitability in late 2025: Q3 2025 net income available to common shareholders was $17.31M and Q4 2025 was $1.69M, suggesting an earnings inflection in the near term.
Dilution risk: 2025 data show weighted-average basic/diluted shares around 314M, indicating ongoing equity dilution for existing holders.
Leverage is moderate but sizable: Long‑term debt near $392M versus cash around $191M (Q3 2025), implying a net debt position of about $201M.
Profitability remains sensitive to spend: SG&A and R&D together amount to a large portion of revenue in most quarters, keeping operating income modest despite strong gross margins.
Financing activity variability: Some quarters show financing inflows, others outflows, indicating ongoing reliance on external funding to support operations.
Healthy liquidity headroom, but watchable burn: Total current assets around $594M and total current liabilities around $199M (Q3 2025), implying a solid working capital cushion.
Net income trend still negative on a trailing basis: Despite late‑2025 improvements, the company has a history of annual losses and large accumulated deficits, reflecting ongoing R&D-driven burn and equity depreciation.

05/07/26 04:57 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Amicus Therapeutics' Financials

When does Amicus Therapeutics' financial year end?

According to the most recent income statement we have on file, Amicus Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

How has Amicus Therapeutics' net income changed over the last 10 years?

Amicus Therapeutics' net income appears to be on a downward trend, with a most recent value of -$27.11 million in 2025, falling from -$68.93 million in 2014. The previous period was -$56.11 million in 2024. See where experts think Amicus Therapeutics is headed by visiting Amicus Therapeutics' forecast page.

What is Amicus Therapeutics' operating income?

Amicus Therapeutics' total operating income in 2025 was $32.79 million, based on the following breakdown:

Total Gross Profit: $561.28 million
Total Operating Expenses: $528.49 million

How has Amicus Therapeutics' revenue changed over the last 10 years?

Over the last 10 years, Amicus Therapeutics' total revenue changed from $1.22 million in 2014 to $634.21 million in 2025, a change of 51,714.5%.

How much debt does Amicus Therapeutics have?

Amicus Therapeutics' total liabilities were at $675.63 million at the end of 2025, a 14.3% increase from 2024, and a 20.5% increase since 2015.

How much cash does Amicus Therapeutics have?

In the past 10 years, Amicus Therapeutics' cash and equivalents has ranged from $49.06 million in 2017 to $246.99 million in 2023, and is currently $214.01 million as of their latest financial filing in 2025.

How has Amicus Therapeutics' book value per share changed over the last 10 years?

Over the last 10 years, Amicus Therapeutics' book value per share changed from 2.78 in 2015 to 0.89 in 2025, a change of -68.1%.

Related Companies

Financial statements for NASDAQ:FOLD last updated on 2/22/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amicus Therapeutics (FOLD) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Amicus Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amicus Therapeutics (FOLD) Financials

Annual Income Statements for Amicus Therapeutics

Quarterly Income Statements for Amicus Therapeutics

Annual Cash Flow Statements for Amicus Therapeutics

Quarterly Cash Flow Statements for Amicus Therapeutics

Annual Balance Sheets for Amicus Therapeutics

Quarterly Balance Sheets for Amicus Therapeutics

Annual Metrics And Ratios for Amicus Therapeutics

Quarterly Metrics And Ratios for Amicus Therapeutics

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Amicus Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools